Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
Identifieur interne : 002B99 ( Main/Exploration ); précédent : 002B98; suivant : 002C00Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
Auteurs : Yoshiaki Furukawa [Canada] ; James J. Filiano ; Stephen J. KishSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2004.
English descriptors
- KwdEn :
- Amantadine (therapeutic use), Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Child, Chorea (complications), Chorea (drug therapy), Dopamine Agents (therapeutic use), Dyskinesia, Drug-Induced (drug therapy), Dyskinesia, Drug-Induced (etiology), GTP Cyclohydrolase (genetics), Heterozygote, Humans, Levodopa (adverse effects), Male, Parkinson Disease (drug therapy), Parkinson Disease (genetics), Pedigree, Phenotype, Point Mutation (genetics).
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , genetics : GTP Cyclohydrolase.
- chemical , therapeutic use : Amantadine, Antiparkinson Agents, Dopamine Agents.
- complications : Chorea.
- drug therapy : Chorea, Dyskinesia, Drug-Induced, Parkinson Disease.
- etiology : Dyskinesia, Drug-Induced.
- genetics : Parkinson Disease, Point Mutation.
- Child, Heterozygote, Humans, Male, Pedigree, Phenotype.
Abstract
Amantadine suppressed severe levodopa-induced choreic dyskinesia, which developed at initiation of levodopa therapy, in two siblings manifesting dystonia with motor delay phenotype of GTP cyclohydrolase I deficiency caused by compound heterozygous GCH1 mutations. Our finding suggests a beneficial effect of amantadine on this type of dyskinesia frequently observed in relatively severe dopamine-deficient metabolic disorders.
DOI: 10.1002/mds.20194
PubMed: 15389992
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001325
- to stream PubMed, to step Curation: 001325
- to stream PubMed, to step Checkpoint: 001325
- to stream Ncbi, to step Merge: 000459
- to stream Ncbi, to step Curation: 000459
- to stream Ncbi, to step Checkpoint: 000459
- to stream Main, to step Merge: 002F59
- to stream Main, to step Curation: 002B99
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.</title><author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name><affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health-Clarke Division, Toronto, Ontario, Canada. yoshiaki_furukawa@camh.net</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health-Clarke Division, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Filiano, James J" sort="Filiano, James J" uniqKey="Filiano J" first="James J" last="Filiano">James J. Filiano</name></author><author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J" last="Kish">Stephen J. Kish</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15389992</idno><idno type="pmid">15389992</idno><idno type="doi">10.1002/mds.20194</idno><idno type="wicri:Area/PubMed/Corpus">001325</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001325</idno><idno type="wicri:Area/PubMed/Curation">001325</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001325</idno><idno type="wicri:Area/PubMed/Checkpoint">001325</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001325</idno><idno type="wicri:Area/Ncbi/Merge">000459</idno><idno type="wicri:Area/Ncbi/Curation">000459</idno><idno type="wicri:Area/Ncbi/Checkpoint">000459</idno><idno type="wicri:doubleKey">0885-3185:2004:Furukawa Y:amantadine:for:levodopa</idno><idno type="wicri:Area/Main/Merge">002F59</idno><idno type="wicri:Area/Main/Curation">002B99</idno><idno type="wicri:Area/Main/Exploration">002B99</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.</title><author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name><affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health-Clarke Division, Toronto, Ontario, Canada. yoshiaki_furukawa@camh.net</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health-Clarke Division, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Filiano, James J" sort="Filiano, James J" uniqKey="Filiano J" first="James J" last="Filiano">James J. Filiano</name></author><author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J" last="Kish">Stephen J. Kish</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amantadine (therapeutic use)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Child</term><term>Chorea (complications)</term><term>Chorea (drug therapy)</term><term>Dopamine Agents (therapeutic use)</term><term>Dyskinesia, Drug-Induced (drug therapy)</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>GTP Cyclohydrolase (genetics)</term><term>Heterozygote</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Male</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (genetics)</term><term>Pedigree</term><term>Phenotype</term><term>Point Mutation (genetics)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>GTP Cyclohydrolase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amantadine</term><term>Antiparkinson Agents</term><term>Dopamine Agents</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Chorea</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Chorea</term><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Parkinson Disease</term><term>Point Mutation</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Child</term><term>Heterozygote</term><term>Humans</term><term>Male</term><term>Pedigree</term><term>Phenotype</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Amantadine suppressed severe levodopa-induced choreic dyskinesia, which developed at initiation of levodopa therapy, in two siblings manifesting dystonia with motor delay phenotype of GTP cyclohydrolase I deficiency caused by compound heterozygous GCH1 mutations. Our finding suggests a beneficial effect of amantadine on this type of dyskinesia frequently observed in relatively severe dopamine-deficient metabolic disorders.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Filiano, James J" sort="Filiano, James J" uniqKey="Filiano J" first="James J" last="Filiano">James J. Filiano</name><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J" last="Kish">Stephen J. Kish</name></noCountry><country name="Canada"><noRegion><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B99 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002B99 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:15389992
|texte= Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:15389992" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |